Plant leaf being placed under microscope

Our Technologies

Innovation for game-changing medicine development

We want to create a future where effective vaccines are developed faster, reach more patients and save more lives

Our plant-based vaccine expression system

Our vaccine development platform uses protein subunits presented by a TMV vector. We are evaluating impacts and potential benefits of this approach on vaccine developments.

Platform Goals

1


Speed

Design and develop vaccines within a ~6-8 week period that meet quality & consistency standards

2


Cost-effectiveness

Cost-effective manufacturing & distribution

3


Robust & flexible

Demonstrate an ability to express an expanding list of viral, bacterial and cancer antigens

4


Scalable

Rapidly increase number of plants to match demand needs

Our Process: A plant-expression system for producing vaccines

We use a plant-based production process for our vaccines and other biologics.

Click Through
To Learn Our Process

Modified TMV (Tobacco Mosaic Virus)

AntigenIdentification
VectorBuilding
Incubation
Extraction
Conjugation
DrugRelease

Genetic Construct (For The Protein)

About the Tobacco Mosaic Virus

We use a proprietary method to chemically join a protein from our pathogen of interest (the antigen) to a modified form of the Tobacco Mosaic Virus (TMV) to form the vaccine drug substance.

Potential impacts under investigation

  • Temperature stability:
    We are investigating temperature stability of our vaccines and whether they have the potential to be stored at room temperature.
  • Product profile:
    TMV is non-infective to mammals and humans.
  • Antigen presentation:
    We are exploring the potential for more robust dendritic cell uptake and activation driven by using TMV in our vaccines.
  • Potential for boosting:
    Because TMV has not shown any evidence of neutralizing antibodies, we are examining the potential for repeated use in boosting.

Citation: TMV – modified Tobacco Mosaic Virus; Source: Banik S, et al. (2015) Development of a Multivalent Subunit Vaccine against Tularemia modified Tobacco Mosaic Virus; Source: Banik S, et al. (2015) Development of a Multivalent Subunit Vaccine against Tularemia modified Tobacco Mosaic Virus; Source: Banik S, et al. (2015)